Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review
Clinical Obesity · 2026
DOI: 10.1111/cob.70042 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Obesity, 2026. Verfasst von Geeta Pardeshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Overweight, Tirzepatide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Tirzepatide provides superior efficacy in weight reduction and metabolic control compared to existing therapies. The present systematic review assessed the effect of Tirzepatide on the risk of developing type 2 diabetes mellitus (T2DM) among people living with obesity or overweight. Six major databases [MEDLINE (PubMed), ClinicalTrials.gov , EMBASE, Scopus, Web of Science and Cochrane Library] were searched for potential studies published till 10 July 2025. Two‐stage dual screening with third‐person adjudication was adopted for screening of studies. PROSPERO ID: CRD42024614466. RoB 2.0 and the Newcastle‐Ottawa Scale were used to assess the quality of randomised controlled trials (RCTs) and cohort studies, respectively. Database search yielded 2601 studies, among which three studies were eligible (one RCT and two cohort studies) for systematic review. The hazard ratio (HR) for the new‐onset diabetes at 12 months following the Tirzepatide intake was significantly lower than that of the Semaglutide group of patients (HR = 0.73, p < 0.001 [95% CI: 0.58–0.92]). The risk of the new‐onset diabetes for 176 weeks (HR = 0.07, p < 0.001 [95% CI: < 0.01–0.1]) and 193 weeks (HR = 0.12, p < 0.001 [95% CI: 0.1–0.2]) following the Tirzepatide intake was significantly lower than that of the placebo group of patients. Tirzepatide might have significant efficacy in the prevention of T2DM in patients with obesity or overweight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Community Medicine, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India.
- Department of Community Medicine, KIMS, Karad, India.
- South Asia Field Epidemiology and Technology Network, Inc., (SAFETYNET), Chennai, India.
- Department of Community Medicine, Maulana Azad Medical College, New Delhi, India.
- Department of Pharmacology, AIIMS, Bilaspur, India.
- Technical Resource Centre, Centre for Evidence based Guidelines, All India Institute of Medical Sciences, Nagpur, India.
ORCID-Profile: Geeta Pardeshi, Uddhav T Kumbhar, Mogan Kaviprawin, Aninda Debnath, Ashok Kumar Dubey, Kalyani Deshmukh, Chanchal Goyal, Aravind P Gandhi
Zitieren
APA
Pardeshi, G., Kumbhar, U. T., Kaviprawin, M., Debnath, A., Dubey, A. K., Deshmukh, K., Goyal, C., & Gandhi, A. P. (2026). Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review. Clinical Obesity. https://doi.org/10.1111/cob.70042
Vancouver
Pardeshi G, Kumbhar UT, Kaviprawin M, Debnath A, Dubey AK, Deshmukh K, et al. Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review. Clinical Obesity. 2026. doi:10.1111/cob.70042
BibTeX
@article{Pardeshi2026,
author = {Pardeshi, Geeta and Kumbhar, Uddhav T and Kaviprawin, Mogan and Debnath, Aninda and Dubey, Ashok Kumar and Deshmukh, Kalyani and Goyal, Chanchal and Gandhi, Aravind P},
title = {Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review},
journal = {Clinical Obesity},
year = {2026},
doi = {10.1111/cob.70042}
}
EUVIMED